Efficacy of Dapagliflozin in Southern Europe Across the Spectrum of Characteristics of Type 2 Diabetes: An International Real-World Analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy of Dapagliflozin in Southern Europe Across the Spectrum of Characteristics of Type 2 Diabetes: An International Real-World Analysis

Published:2022-11 Issue: Volume:Volume 15 Page:3533-3541
ISSN:1178-7007
Container-title:Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
language:en
Short-container-title:DMSO

Author:

Fadini Gian Paolo^ORCID,Morales Cristobal,Caballero Irene,González Beatriz^ORCID,Tentolouris Nikolaos^ORCID,Consoli Agostino

Publisher

Informa UK Limited

Subject

Pharmacology,Internal Medicine

Reference23 articles.

1. International Diabetes Foundation. Available from: https://www.diabetesatlas.org/en/. Accessed February 23, 2021.

2. Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

3. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis;Acta Diabetologica;2024-04-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP